Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Ticker
$BLTE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
25
ISIN
US07782B1044
Website
BLTE Metrics
BasicAdvanced
$1.9B
-
-$1.37
-1.48
-
Price and volume
Market cap
$1.9B
Beta
-1.48
52-week high
$74.15
52-week low
$49.00
Average daily volume
38K
Financial strength
Current ratio
25.981
Interest coverage (TTM)
-2,359.25%
Profitability
EBITDA (TTM)
-47.01
Management effectiveness
Return on assets (TTM)
-22.23%
Return on equity (TTM)
-33.43%
Valuation
Price to book
12.16
Price to tangible book (TTM)
12.16
Growth
Earnings per share change (TTM)
20.58%
3-year earnings per share growth (CAGR)
16.72%
Bulls say / Bears say
Belite Bio's lead candidate, Tinlarebant, has received a positive interim data analysis from the Phase 3 DRAGON trial, with a DSMB recommendation to seek accelerated regulatory approval, indicating potential for expedited market entry. (TipRanks)
Analysts at Maxim Group have raised their price target for Belite Bio to $110.00, reflecting strong confidence in the company's growth prospects and pipeline advancements. (Defense World)
Belite Bio's stock has reached an all-time high of $70.4, demonstrating robust investor confidence and positive market sentiment towards the company's future performance. (Investing.com)
Cantor Fitzgerald has lowered its FY2025 earnings per share estimates for Belite Bio to ($1.36), indicating concerns about the company's near-term profitability. (Defense World)
Belite Bio reported a net loss of $9.5 million in Q2 2024, slightly higher than expected due to a development milestone payment, which may raise concerns about financial stability. (Investing.com)
The company's earnings per share for the quarter ending March 17th, 2025, were ($0.32), missing analysts' consensus estimates of ($0.30), suggesting potential challenges in meeting financial expectations. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BLTE News
AllArticlesVideos
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
GlobeNewsWire·1 month ago
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Belite Bio Inc. ADS stock?
Belite Bio Inc. ADS (BLTE) has a market cap of $1.9B as of June 30, 2025.
What is the P/E ratio for Belite Bio Inc. ADS stock?
The price to earnings (P/E) ratio for Belite Bio Inc. ADS (BLTE) stock is 0 as of June 30, 2025.
Does Belite Bio Inc. ADS stock pay dividends?
No, Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Belite Bio Inc. ADS dividend payment date?
Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Belite Bio Inc. ADS?
Belite Bio Inc. ADS (BLTE) has a beta rating of -1.48. This means that it has an inverse relation to market volatility.